InfoComm EDGE Dubai Showcases AV Solutions Enabling Biotech Collaboration, Aiding PDS Biotechnology
- InfoComm EDGE could provide AV solutions PDS Biotechnology needs for complex clinical programs and remote GCC collaborations.
- Demonstrations help PDS decision-makers visualize remote patient monitoring, virtual tumor boards, staff training, and secure clinical trial coordination.
- Standards-based, demonstrable systems offer PDS a way to align operations, regulatory compliance, and patient-facing technologies in the region.
Dubai Pro AV Showcase Signals New Tools for Biotech Collaboration
InfoComm EDGE’s experiential format in Dubai could provide practical audiovisual solutions that companies such as PDS Biotechnology need to run complex clinical programs and remote collaborations across the Gulf Cooperation Council (GCC), industry executives say. AVIXA is hosting the two‑day event on Oct. 27–28, 2026 at the Festival Arena to let senior buyers across government, enterprise, education, retail, leisure and entertainment see, touch and experience standards‑aligned pro AV innovation in buyer‑focused activations rather than vendor pitches.
InfoComm EDGE’s approach is particularly relevant to the biotech sector because it emphasizes integrated, narrative‑led demonstrations that mirror end‑to‑end project delivery. The Festival Arena layout centres a live activation stage and supporting pods rather than a traditional trade‑show grid, allowing systems integrators to show combined audiovisual, telepresence and data‑visualization workflows. For PDS Biotechnology, which operates in regulated clinical and research environments, such demonstrations help decision‑makers visualise solutions for remote patient monitoring, virtual tumour boards, staff training and secure clinical trial coordination before procurement and deployment decisions.
The event’s co‑creative model, in which local integrators design and staff activations, aims to reduce implementation risk and improve outcomes by highlighting standards, integration and delivery excellence. AVIXA Chief Executive David Labuskes points to the GCC’s appetite and resources for innovation, while Event Director Cara Turner stresses that high‑level buyers struggle to picture complex systems from booth displays. For PDS and peers in the biotech and healthcare sectors, the emphasis on demonstrable, standards‑based systems offers a path to align operational needs, regulatory compliance and patient‑facing technologies in the region.
Other industry implications
InfoComm EDGE opens an avenue for manufacturers and integrators to partner directly with healthcare and life‑sciences buyers, presenting opportunities to influence specification and procurement for new facilities and retrofits. The narrative‑led format is pitched at reducing risk in capital projects, an issue biotech firms often cite when planning trial sites, training centres or telemedicine hubs.
Event details and participation
Branded “Where the Art of the Possible Becomes Reality,” the two‑day event uses more than 7,200 square metres of indoor and outdoor space and invites AV integrators, manufacturers and prospective attendees to submit designs, sponsorships and registration inquiries at AVIXA’s InfoComm EDGE Dubai web portal.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

